Back to Search Start Over

Development and evaluation of deuterated [ 18 F]JHU94620 isotopologues for the non-invasive assessment of the cannabinoid type 2 receptor in brain.

Authors :
Gündel D
Maqbool M
Teodoro R
Ludwig FA
Heerklotz A
Toussaint M
Deuther-Conrad W
Bormans G
Brust P
Kopka K
Moldovan RP
Source :
EJNMMI radiopharmacy and chemistry [EJNMMI Radiopharm Chem] 2024 Dec 23; Vol. 9 (1), pp. 91. Date of Electronic Publication: 2024 Dec 23.
Publication Year :
2024

Abstract

Background: The cannabinoid type 2 receptors (CB2R) represent a target of increasing importance in neuroimaging due to its upregulation under various neuropathological conditions. Previous evaluation of [ <superscript>18</superscript> F]JHU94620 for the non-invasive assessment of the CB2R availability by positron emission tomography (PET) revealed favourable binding properties and brain uptake, however rapid metabolism, and generation of brain-penetrating radiometabolites have been its main limitations. To reduce the bias of CB2R quantification by blood-brain barrier (BBB)-penetrating radiometabolites, we aimed to improve the metabolic stability by developing -d <subscript>4</subscript> and -d <subscript>8</subscript> deuterated isotopologues of [ <superscript>18</superscript> F]JHU94620.<br />Results: The deuterated [ <superscript>18</superscript> F]JHU94620 isotopologues showed improved metabolic stability avoiding the accumulation of BBB-penetrating radiometabolites in the brain over time. CB2R-specific binding with K <subscript>D</subscript> values in the low nanomolar range was determined across species. Dynamic PET studies revealed a CB2R-specific and reversible uptake of [ <superscript>18</superscript> F]JHU94620-d <subscript>8</subscript> in the spleen and to a local hCB2R(D80N) protein overexpression in the striatal region in rats.<br />Conclusion: These results support further investigations of [ <superscript>18</superscript> F]JHU94620-d <subscript>8</subscript> in pathological models and tissues with a CB2R overexpression as a prerequisite for clinical translation.<br />Competing Interests: Declarations. Ethics approval and consent to participate: All studies involving animals were carried out according to the national law on the protection of animals and were approved by the responsible authorities (Landesdirektion Sachsen, No. DD24.1-5131/446/19, TVV 18/18), CD-1 mice and Wistar rats were obtained from the Medizinisch-Experimentelles-Zentrum at Universität Leipzig (Leipzig, Germany) and a pig (German Landrace x German Large White) was obtained from the Lehr- und Versuchsgut Oberholz (Großpösna, Germany). Animals were kept under standard conditions with free access to water and food. Consent for publication: Not applicable. Competing interests: The authors declare that they have no competing interests.<br /> (© 2024. The Author(s).)

Details

Language :
English
ISSN :
2365-421X
Volume :
9
Issue :
1
Database :
MEDLINE
Journal :
EJNMMI radiopharmacy and chemistry
Publication Type :
Academic Journal
Accession number :
39714717
Full Text :
https://doi.org/10.1186/s41181-024-00319-2